Journey Medical (DERM) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Journey Medical (DERM) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 20.9% versus a loss of 73.0%. Journey Medical is the larger company by market cap ($181.5 million vs $164.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | NBP |
|---|---|---|
| Share price | $6.43 | $1.42 |
| Market cap | $181.48M | $164.14M |
| 1-day change | +8.07% | +3.28% |
| YTD return | -22.83% | -65.58% |
| 1-year return | -20.88% | -72.98% |
| 5-year return | — | -97.92% |
| EPS (TTM) | $-0.22 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.56 | $6.79 |
| 52-week low | $4.31 | $1.31 |
| Distance from 52-week high | -32.71% | -79.16% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +113.84% | +536.04% |
| Average volume | 184.01K | 382.99K |
| Shares outstanding | 22.22M | 116.00M |
| Employees | 58 | 30 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DERM has outperformed NBP by 52.1 percentage points over the past year.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
DERM vs NBP FAQ
Which is bigger, Journey Medical or NovaBridge Biosciences?
Journey Medical (DERM) is larger, with a market capitalization of $181.48M compared with $164.14M for NovaBridge Biosciences (NBP).
Which stock has performed better over the past year, DERM or NBP?
DERM returned -20.88% over the past 12 months, compared with -72.98% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and NovaBridge Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.